[{"data":1,"prerenderedAt":191},["ShallowReactive",2],{"drug-dronabinol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":51,"contraindications":90,"warnings":100,"renal":108,"monitoring":109,"interactions":110,"review":111,"examples":114,"atc":120,"iran":122,"usApproval":134,"links":140,"populations":156},"dronabinol",1,{"fa":7,"en":8},"درونابینول","Dronabinol","alimentary-metabolism",{"fa":11,"en":12},"کانابینوئید (THC مصنوعی)","Cannabinoid (synthetic THC)",[14],{"name":15,"market":16},"Marinol","US",[18,19,7,20],"marinol","مارینول","THC",[22,35,43],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"cap-2-5","capsule","oral","2.5 mg capsule",{"amount":28,"unit":29,"perUnit":24},2.5,"mg",[16],[32],{"source":33,"section":34},"fda-marinol","3",{"id":36,"form":24,"route":25,"label":37,"concentration":38,"markets":40,"refs":41},"cap-5","5 mg capsule",{"amount":39,"unit":29,"perUnit":24},5,[16],[42],{"source":33,"section":34},{"id":44,"form":24,"route":25,"label":45,"concentration":46,"markets":48,"refs":49},"cap-10","10 mg capsule",{"amount":47,"unit":29,"perUnit":24},10,[16],[50],{"source":33,"section":34},[52,75],{"id":53,"disease":54,"label":55,"population":58,"type":62,"unit":29,"dose":63,"refs":65,"notes":68},"aids","aids-anorexia",{"fa":56,"en":57},"بی‌اشتهایی و کاهش وزن در ایدز بزرگسال — ۲٫۵ mg دو بار، ۱ ساعت پیش از ناهار و شام","AIDS anorexia with weight loss, adults — 2.5 mg twice daily, 1 h before lunch and dinner",{"minAge":59},{"value":60,"unit":61},18,"year","fixed",{"perDose":28,"perDoseMax":47,"dosesPerDay":64},2,[66],{"source":33,"section":67},"2.1",[69],{"text":70,"refs":73},{"fa":71,"en":72},"سالمند یا عدم تحمل: ۲٫۵ mg یک بار پیش از شام یا هنگام خواب. حداکثر ۱۰ mg دو بار.","Elderly or intolerant: 2.5 mg once before dinner or at bedtime. Max 10 mg twice daily.",[74],{"source":33,"section":67},{"id":76,"disease":76,"label":77,"population":80,"type":82,"unit":29,"dose":83,"refs":87},"cinv",{"fa":78,"en":79},"تهوع شیمی‌درمانی مقاوم به ضدتهوع‌های معمول — شروع ۵ mg\u002Fm² ۱ تا ۳ ساعت پیش از شیمی‌درمانی، سپس هر ۲ تا ۴ ساعت (۴ تا ۶ دوز\u002Fروز)","CINV refractory to conventional antiemetics — start 5 mg\u002Fm² 1–3 h before chemotherapy, then every 2–4 h (4–6 doses\u002Fday)",{"minAge":81},{"value":60,"unit":61},"notCalculated",{"reason":84},{"fa":85,"en":86},"دوز بر اساس سطح بدن و به نزدیک‌ترین کپسول ۲٫۵ mg گرد می‌شود؛ سالمند ۲٫۵ mg\u002Fm² یک بار. اولین دوز ناشتا.","BSA-based dose rounded to the nearest 2.5 mg capsule; elderly 2.5 mg\u002Fm² once. First dose on an empty stomach.",[88],{"source":33,"section":89},"2.2",[91],{"id":92,"severity":93,"text":94,"refs":97},"hyper","block",{"fa":95,"en":96},"سابقه حساسیت به درونابینول یا روغن کنجد.","History of hypersensitivity to dronabinol or sesame oil.",[98],{"source":33,"section":99},"4",[101],{"text":102,"refs":105},{"fa":103,"en":104},"عوارض عصبی-روانی (گیجی، سرخوشی، سایکوز)؛ ناپایداری همودینامیک؛ تشنج؛ سوءمصرف چندگانه؛ تهوع و استفراغ متناقض.","Neuropsychiatric reactions (confusion, euphoria, psychosis); haemodynamic instability; seizures; multiple substance abuse; paradoxical nausea and vomiting.",[106],{"source":33,"section":107},"5",[],[],[],{"status":112,"reviewer":113,"date":113},"unverified",null,[115],{"regimen":53,"formulation":23,"input":116,"expect":119},{"ageYears":117,"weightKg":118},40,60,{"perDose":28,"tabletsPerDoseRounded":5,"upperPerDose":47},[121],"A04AD10",{"status":123,"forms":124,"refs":129},"registered",[125],{"code":126,"en":127,"fa":128},"08121","DRONABINOL 5MG TAB","قرص درونابینول ۵ میلی‌گرم",[130],{"source":131,"section":132,"url":133},"darooyab-generic","G-2578\u002FDronabinol","https:\u002F\u002Fwww.darooyab.ir\u002FG-2578\u002FDronabinol",{"kind":135,"refs":136,"id":139},"NDA",[137],{"source":33,"section":138},"SPL approval \u002F marketing category","NDA018651",[141,144,148,151,154],{"kind":142,"url":143,"label":139},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=018651",{"kind":145,"url":146,"label":147},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d0efeeec-640d-43c3-8f0a-d31324a11c68","FDA Marinol",{"kind":149,"url":150,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607054.html",{"kind":152,"url":153,"label":121},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A04AD10",{"kind":155,"url":133,"label":8},"darooyab",{"pregnancy":157,"lactation":166,"pediatric":175,"geriatric":183},{"level":158,"text":159,"quote":162,"refs":163},"avoid",{"fa":160,"en":161},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary MARINOL, a synthetic cannabinoid, may cause fetal harm.",[164],{"source":33,"section":165},"8.1",{"level":167,"text":168,"quote":171,"refs":172},"caution",{"fa":169,"en":170},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary For mothers infected with the Human Immunodeficiency Virus (HIV), the Centers for Disease Control and Prevention recommends that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV.",[173],{"source":33,"section":174},"8.2",{"level":167,"text":176,"quote":179,"refs":180},{"fa":177,"en":178},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of MARINOL have not been established in pediatric patients.",[181],{"source":33,"section":182},"8.4",{"level":167,"text":184,"quote":187,"refs":188},{"fa":185,"en":186},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of falls, decreased hepatic, renal, or cardiac function, increased sensitivity to psychoactive effects, and of concomitant disease or other drug therapy [see …",[189],{"source":33,"section":190},"8.5",1792191539622]